Global Vutrisiran Market Expected to Hit $1.18 Billion by 2030, Growing at 12% CAGR

 The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

What Are the Projections for Vutrisiran Market Size and CAGR During 2026-2030?
The vutrisiran market size has grown rapidly in recent years. It will grow from $0.67 billion in 2025 to $0.75 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to breakthrough siRNA approvals, unmet needs in hATTR amyloidosis, limitations of liver transplant options, expansion of orphan drug policies, improved genetic diagnosis.

The vutrisiran market size is expected to see rapid growth in the next few years. It will grow to $1.18 billion in 2030 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to growing rare disease awareness, expansion of rna therapeutics pipeline, rising adoption of long-acting therapies, increased genetic screening, growth in specialty care centers. Major trends in the forecast period include growing adoption of rna interference therapies, increased focus on rare genetic disorders, expansion of long-interval dosing treatments, rising demand for targeted amyloidosis therapies, increased use of subcutaneous rna drugs.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/vutrisiran-global-market-report

What Are the Key Market Drivers and Opportunities in the Vutrisiran Market?
The increasing investment in research and development is expected to propel the growth of the vutrisiran market going forward. Research and development refers to innovating and improving products, services, or processes through systematic investigation and experimentation. The increasing investment in research and development (R&D)is due to government initiatives and funding, growing healthcare and pharmaceutical needs, sustainability, and environmental concerns. Research and development funding allows pharmaceutical companies to conduct clinical trials, demonstrating the drug's long-term benefits and safety, leading to broader regulatory approvals. Additionally, RNA interference (RNAi) technology advancements improve the drug's precision, reducing side effects and increasing patient adoption. For instance, April 2025, Office for National Statistics, a UK-based government department, the UK government’s net spending on research and development (R&D) reached approximately US $22.9 billion (£17.4 billion) in 2023, up from around US $20.0 billion (£16.1 billion) in 2022. Therefore, the increasing investment in research and development is driving the growth of the vutrisiran.

Which Are the Leading Segments in the Vutrisiran Market?
The vutrisiran market covered in this report is segmented –

1) By Drug Class: RNA Interference (RNAi) Therapeutics, GalNAc-Conjugated Nucleic Acid Drugs, Synthetic RNA-Based Therapeutics
2) By Route Of Administration: Injectable, Subcutaneous
3) By Patient Demographics: Adult, Geriatric
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:
1) By RNA Interference (RNAi) Therapeutics: Small Interfering RNA (siRNA) Drugs, Gene-Silencing RNA Therapies
2) By GalNAc-Conjugated Nucleic Acid Drugs: GalNAc-Conjugated siRNA Therapies, Hepatocyte-Targeted RNA Therapeutics
3) By Synthetic RNA-Based Therapeutics: Chemically Modified RNA Therapeutics, Long-Acting RNA Therapeutics

Which Emerging Trends Are Driving the Vutrisiran Market?
Major companies operating in the vutrisiran market are expanding its use into cardiomyopathy via regulatory approval, such as supplemental indication for ATTR CM, to broaden the patient base and maximize long-term value. A supplemental new drug application (sNDA) is a regulatory filing that extends an approved drug's use to new indications. For instance, in March 2025, Alnylam Pharmaceuticals, a US-based biotech company, received FDA approval for AMVUTTRA (vutrisiran) in adult patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM), becoming the first RNAi therapeutic approved for both polyneuropathy and cardiomyopathy forms of the disease. Therefore, the extension into cardiomyopathy is a key trend driving growth in the vutrisiran market by increasing its clinical reach and patient access.

Who Are the Leading Companies in the Vutrisiran Industry by Revenue?
Major companies operating in the vutrisiran market are Alnylam Pharmaceuticals Inc

Get the full vutrisiran market report here:
https://www.thebusinessresearchcompany.com/report/vutrisiran-global-market-report

Which Regions Are Driving the Most Demand in the Vutrisiran Market?
North America was the largest region in the vutrisiran market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vutrisiran market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn